<DOC>
	<DOCNO>NCT01716585</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy ABT-450 , ritonavir ABT-267 ( ABT-450/r/ABT-267 ; ABT-267 also know ombitasvir ) ABT-333 ( also know dasabuvir ) co-administered ribavirin ( RBV ) hepatitis C virus genotype 1 infected treatment-naïve adult .</brief_summary>
	<brief_title>A Study Evaluate Chronic Hepatitis C Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Females must postmenopausal least 2 year surgically sterile practice specific form birth control Chronic hepatitis C , genotype 1infection HCV RNA level great 10,000 IU/mL screen Subject never receive antiviral treatment hepatitis C infection No evidence liver cirrhosis Positive screen drug alcohol Significant sensitivity drug Use contraindicate medication within 2 week dose Certain predefined abnormal laboratory test Positive hepatitis B surface antigen antihuman immunodeficiency virus antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Hepatitis C Virus</keyword>
	<keyword>Hepatitis C Genotype 1</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Treatment-Naïve</keyword>
	<keyword>Interferon-Free</keyword>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>Viekira Pak</keyword>
	<keyword>ombitasvir</keyword>
	<keyword>paritaprevir</keyword>
	<keyword>dasabuvir</keyword>
</DOC>